Clinuvel Pharmaceuticals
(ASX:CUV) today reported that its CEO Philippe Wolgen will stay with the company for three more years.
As its long-serving key executive, Dr Wolgen has steered the Company since its restructure in 2005 to its current successful position.
Clinuvel’s Head of Remuneration Committee Mr Willem Blijdorp says “Amongst its international peers, CLINUVEL ranks near the median value of total annual remuneration awarded to its CEO.”
Shares in Clinuvel Pharmaceuticals
(ASX:CUV) are trading 2.1 per cent lower at $25.48.
